S. Kaye

Molecular Biology · 2000–2011

A researcher in the Science corpus: 10 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

Whom S. Kaye trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Michael O. Hengartner

Who trusts S. Kaye overall

  1. Shaloam Dasari
  2. P. Tchounwou

Papers from S. Kaye's perspective

Ordered by how strongly the researchers S. Kaye trusts endorse each paper. Same corpus, a different order for every researcher.

  1. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. (New England Journal of Medicine)
  2. The biochemistry of apoptosis (Nature)
  3. Proliferation, cell cycle and apoptosis in cancer (Nature)
  4. Mutations of the BRAF gene in human cancer (Nature)
  5. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer… (Journal of the National Cancer Institute)
  6. Nonparametric Estimation from Incomplete Observations
  7. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis (Cancer Research)
  8. Prognostic Impact of Histologic Subtyping of Adult Renal Epithelial Neoplasms: An Experience of 405 Cases (American Journal of Surgical Pathology)
  9. BRAF and RAS mutations in human lung cancer and melanoma. (Cancer Research)
  10. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. (Journal of Clinical Oncology)

Their papers